TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31531997
Drug: Standard polymeric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard polymeric supplements (3 supplements/day for 5 days)
Study: 31531997
Drug: Immunonutrition and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunonutrition and Standard polymeric supplements
Study: 30848558
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) plus nonbiologic background medication (NBBM)
Study: 30848558
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus nonbiologic background medication (NBBM)
Study: 26803169
Drug: SeY-100/d (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: SeY-100/d (100 μg Se/day)
Study: 26803169
Drug: SeY-50/d (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SeY-50/d (50 μg Se/day)
Study: 26803169
Drug: SeY-200/d (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SeY-200/d (200 μg Se/day)
Study: 26803169
Drug: SeO-50/d (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SeO-50/d (50 μg Se/day)
Study: 26803169
Drug: Se supplementation
Normalized name: selenomethionine Se 75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Se supplementation (various doses)
Study: 21519309
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (1 mg/kg per hour) with patient-controlled analgesia morphine for the first 48 hours after surgery
Study: 21519309
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia with patient-controlled analgesia morphine for the first 48 hours after surgery
Study: 10903240
Drug: montelukast at
Approvals — FDA: no, EMA: no, PMDA: no
Description: montelukast at 5 mg/d for 2 days
Study: 9305235
Drug: Mixed weed
Normalized name: ALLERGENIC EXTRACT MIXED WEEDS INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed weed extract (1:2500 wt/vol to 1:10 wt/vol) administered daily for 12 to 16 weeks with 5.2 mg intranasal cromolyn pretreatment.
Study: 8454221
Drug: Parenteral hydralazine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral hydralazine
Study: 3096592
Drug: Terfenadine suspension,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine suspension, 30 mg b.i.d.
Study: 25054430
Drug: Dofetilide (pure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide (pure hERG potassium channel blocker)
Study: 17660482
Drug: digoxin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: digoxin (0.5 mg, then 0.25 mg qd on days 2‐7)
Study: 17660482
Drug: combination vildagliptin/digoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination vildagliptin/digoxin for 7 days
Study: 10999557
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1,000 mg twice daily
Study: 10999557
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 2,000 mg twice daily
Study: 10999557
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1,000 mg and 2,000 mg
Study: 1599635
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate supplementation (1 g for 12 weeks)
Study: 3830333
Drug: Type 1
Normalized name: Type 1 H substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 1 electroconvulsive therapy
Study: 3830333
Drug: Type 2
Normalized name: Type 2 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 2 electroconvulsive therapy
Study: 3830333
Drug: Type 3
Normalized name: Type 3 H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 3 electroconvulsive therapy
Study: 24239386
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation therapy
Study: 24239386
Drug: Standard radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard radiation therapy
Study: 18621791
Drug: Bimatoprost twice
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost twice daily/once daily
Study: 21059740
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (PUFAs) 3 g/day until ECV and 2 g/day thereafter
Study: 18664159
Drug: Cryosurgery followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cryosurgery followed by diclofenac sodium 3% gel for 90 days
Study: 8803370
Drug: Nicotine gum
Normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine gum (2 or 4 mg)
Study: 23943282
Drug: Topical 0.4
Normalized name: fluoride topical 0.4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.4 % glyceryl trinitrate (GTN) ointment every 12 hours for four postoperative weeks
Study: 23943282
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no GTN ointment)
Study: 23943282
Drug: Topical 0.4
Normalized name: fluoride topical 0.4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.4 % glyceryl trinitrate (GTN) ointment
Study: 19796735
Drug: High-dose statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose statin therapy initiated pre-discharge
Study: 20391072
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) program, 6-week duration
Study: 1906746
Drug: Prophylactic administration
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic administration of OKT3
Study: 29170901
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Phototherapy + EXT)
Study: 8384658
Drug: Roxithromycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (150 mg every 12 hours for 7 days)
Study: 29402234
Drug: Structured follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured follow-up by a GP and home care oncology nurse (HON) including a GP consultation before treatment and a minimum of three contacts with the HON during and after treatment.
Study: 22546175
Drug: Wood smoke
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood smoke exposure at 200 μg/m(3)
Study: 22546175
Drug: Wood smoke
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood smoke exposure at 400 μg/m(3)
Study: 18448442
Drug: 0.625‐mg conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625‐mg conjugated equine estrogens (CEEs)
Study: 7386802
Drug: Purified allergen
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified allergen preparation
Study: 28571271
Drug: 0.1% triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% triamcinolone acetonide oral paste thrice daily in tapering doses
Study: 28571271
Drug: curcumin oral
Normalized name: curcumin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: curcumin oral gel thrice daily
Study: 28571271
Drug: curcumin oral
Normalized name: curcumin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: curcumin oral gel six times daily
Study: 26451088
Drug: Probiotic preparation
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic preparation inVag(®) administered vaginally for seven consecutive days
Study: 26451088
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered vaginally for seven consecutive days
Study: 23339578
Drug: 4.5 g
Normalized name: Zosyn 4.5 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 g of larch arabinogalactan preparation (n=101)
Study: 14965858
Drug: Principal Component
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Principal Component Analysis (PCA) applied on multichannel magnetocardiographic (MCG) recordings in patients with MI.
Study: 14965858
Drug: Principal Component
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Principal Component Analysis (PCA) applied on multichannel magnetocardiographic (MCG) recordings in patients with VT.
Study: 14965858
Drug: Principal Component
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Principal Component Analysis (PCA) applied on multichannel magnetocardiographic (MCG) recordings in normals.
Study: 14965858
Drug: Principal Component
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Principal Component Analysis (PCA) applied on multichannel magnetocardiographic (MCG) recordings in patients with CHD.
Study: 11001237
Drug: Fixed regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed regimen of 30 mg mirtazapine at bedtime
Study: 11001237
Drug: Ascending dose
Normalized name: IODINE 1 kg in 1 kg TOPICAL LIQUID [ASCEND]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending dose regimen of mirtazapine (15 mg to 30 mg at bedtime)
Study: 11001237
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens (fixed and ascending dosing)
Study: 9071932
Drug: bFGF 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: bFGF 0.1 mg twice daily
Study: 3098498
Drug: Levonorgestrel 20
Normalized name: ethinyl estradiol-levonorgestrel 20 mcg-90 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 20 mcg/day
Study: 27825381
Drug: Cornerstone program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cornerstone program (case management, trauma-focused cognitive behavioral therapy, mentoring/peer support, community-based practice, stigma and skill development)
Study: 24911076
Drug: Biosimilar G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosimilar G-CSF (Zarzio(®), Sandoz Biopharmaceuticals)
Study: 24911076
Drug: Originator G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Originator G-CSF (Neupogen(®), Amgen)
Study: 23158715
Drug: Oral endotracheal
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral endotracheal intubation (OEI)
Study: 19619073
Drug: Rivastigmine (transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (transdermal patch)
Study: 15711943
Drug: Traditional voice
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional voice treatment
Study: 9449870
Drug: Diethylcarbamazine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylcarbamazine 6 mg/kg
Study: 9449870
Drug: Diethylcarbamazine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylcarbamazine 6 mg/kg plus ivermectin 400 micrograms/kg
Study: 360921
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug therapy (50 mg chlorthalidone, 100 mg chlorthalidone, and 100 mg chlorthalidone plus 0.25 mg reserpine)
Study: 30921982
Drug: Th1-transforaminal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Th1-transforaminal epidural injection (Th1-TFEI)
Study: 30921982
Drug: Th1/2-parasagittal interlaminar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Th1/2-parasagittal interlaminar epidural injection (Th1/2-pILEI)
Study: 22221427
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 micrograms and Beclomethasone 200 micrograms (HFA; metered-dose inhaler) b.i.d. (FB)
Study: 19224761
Drug: 6-mercaptopurine (6MP)/methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mercaptopurine (6MP)/methotrexate (MTX) maintenance therapy
Study: 19224761
Drug: Longer duration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer duration of oral 6MP/MTX maintenance therapy
Study: 19224761
Drug: Average 6MP
Normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average 6MP doses in TPMT wild-type patients
Study: 17301297
Drug: Intravenous methylprednisolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methylprednisolone, 30 mg per kilogram of body weight
Study: 16265829
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (oral and intravenous fluid replacement, NSAIDs, caffeine)
Study: 16265829
Drug: Epidural blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blood patch (EBP)
Study: 11591613
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg and MPA 2.5 mg
Study: 11591613
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg and MPA 5.0 mg
Study: 7875113
Drug: Unilateral electroconvulsive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unilateral electroconvulsive therapy (ECT)
Study: 19783808
Drug: Medication manipulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication manipulation
Study: 16140028
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) inhalation (3 ml 0.1% in PBS)
Study: 16140028
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation (3 ml PBS)
Study: 16140028
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA) inhalation
Study: 1306735
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg 4-HPR daily for 52 weeks
Study: 31970796
Drug: Whole blood
Normalized name: Whole blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole blood treatment
Study: 31970796
Drug: Component therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Component therapy (current standard of care)
Study: 31970796
Drug: Relative risk
Normalized name: (2R*,3S)-rel-1,2,3,4-butanetetroltetranitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relative risk of whole blood compared to component therapy
Study: 30663629
Drug: Outpatient individual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Outpatient individual treatment adherence
Study: 16754834
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (100 ng/mL of plasma)
Study: 16754834
Drug: High-dose ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ketamine (200 ng/mL of plasma)
Study: 1672841
Drug: Antianginal drugs
Normalized name: ANTIANGINALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antianginal drugs (beta-blockers, calcium antagonists, nitrates, alone or in various combinations)
Study: 22772335
Drug: Dopamine D₃
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D₃ receptor antagonist, GSK598809 (175 mg)
Study: 18330846
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) monotherapy, mean maintenance dose 217.2 mg/day
Study: 16322140
Drug: Multisystemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic therapy (MST) for approximately 6 months
Study: 10408847
Drug: Granisetron 3
Normalized name: granisetron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 3 mg intravenous
Study: 10408847
Drug: Prednisolone 25
Normalized name: prednisolone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 25 mg oral plus metopimazine 30 mg oral
Study: 8877895
Drug: Menatetrenone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (15 mg) after meal A (8.8 g fat)
Study: 8877895
Drug: Menatetrenone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (15 mg) after meal B (20.0 g fat)
Study: 8877895
Drug: Menatetrenone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (15 mg) after meal C (34.9 g fat)
Study: 8877895
Drug: Menatetrenone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (15 mg) after meal B (20.0 g fat) without lunch
Study: 8877895
Drug: Menatetrenone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menatetrenone (15 mg) after meal D (53.8 g fat)
Study: 1892404
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics from immediately after surgery until the third day (Group B)
Study: 1892404
Drug: Local sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local sterile antibiotic powder sprinkled into the wound during surgery (Group C)
Study: 1892404
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics from 2 days before surgery until the second day after surgery (Group D)
Study: 1892404
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics (Group A)
Study: 30866108
Drug: Detomidine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine (0.01 mg/kg bwt)
Study: 30866108
Drug: Detomidine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detomidine (0.01 mg/kg bwt) + Butorphanol (0.02 mg/kg bwt)
Study: 30866108
Drug: Saline (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.9% solution, 10 mL)
Study: 28604151
Drug: Diltiazem-Hydrochloride (DTZ)
Normalized name: Diltiazem Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem-Hydrochloride (DTZ) in sustained-release matrix tablets
Study: 27214088
Drug: Eprosartan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (3 and 10 μg/kg/min for 15 min per dose)
Study: 27214088
Drug: Eprosartan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (3 and 10 μg/kg/min for 15 min per dose) with low sodium diet
Study: 27214088
Drug: Eprosartan (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (3 and 10 μg/kg/min for 15 min per dose) with Ang II co-infusion (1 ng/kg/min)
Study: 25075176
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (5 mL) delivered by JetPeel™‐3 followed by multiple injections of BTX‐A (100 units)
Study: 25075176
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (5 mL) and BTX‐A (50 units) delivered together by JetPeel™‐3
Study: 25075176
Drug: Lidocaine delivered
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine delivered by JetPeel™‐3 followed by multiple BTX‐A injections
Study: 18035201
Drug: Lamotrigine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (400 mg daily, titrated over 8 weeks)
Study: 7718463
Drug: 2% ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% ketoconazole shampoo (twice weekly for 2-4 weeks)
Study: 7718463
Drug: 2% ketoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% ketoconazole shampoo (once-weekly, once every other week, alternating with placebo)
Study: 7718463
Drug: Placebo shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo shampoo (once-weekly)
Study: 7718463
Drug: Active/placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active/placebo group (alternating treatment)
Study: 6112386
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid plus dipyridamole (1050 mg + 150 mg/day, group A)
Study: 6112386
Drug: Pentoxifylline (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1200 mg/day, group B)
Study: 26338693
Drug: Aripiprazole (5‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (5‐30 mg/d)
Study: 26338693
Drug: Risperidone (1‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1‐6 mg/d)
Study: 23672956
Drug: Subcutaneous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous hydrocortisone (100 mg)
Study: 23672956
Drug: Intramuscular hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular hydrocortisone (100 mg)
Study: 19434784
Drug: Topical provocation
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical provocation with 15 mg GSTS
Study: 10770199
Drug: L-[3-13C1]sodium lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-[3-13C1]sodium lactate and D-[6,6-D2]glucose infusion
Study: 9354211
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pentazocine i.v.
Study: 9354211
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tilidine i.v.
Study: 28005113
Drug: Tablet questionnaires
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet questionnaires
Study: 25858478
Drug: Colestyramine 4
Normalized name: Colestyramine 4 g powder for oral suspension sachet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestyramine 4 g twice daily
Study: 23565660
Drug: Oral combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combined vitamins for 1 year
Study: 15231980
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg on day 1 and 5 mg/kg on days 2-5)
Study: 15231980
Drug: Erythromycin estolate
Normalized name: Erythromycin Estolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolate (40 mg/kg/day in 3 divided doses for 10 days)
Study: 2517679
Drug: Glucose (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (group G)
Study: 29033560
Drug: Proactive palliative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive palliative care in monthly meetings with a specialized palliative care team (SPCT)
Study: 26149129
Drug: Rosuvastatin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 2.5 mg/day